CyFlow™ CD7 FITC

CyFlow™ CD7 FITC
Laser: Blue
Target Species: Human
Antigen: CD7
Field of Interest: Immunophenotyping
Clone: MEM-186
Regulatory Status: RUO
Alternative Name: gp40
Application: Flow cytometry
Format/Fluorochrome: FITC
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG1
Product number: BT154671

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA VI—WS Code T 6T-015 Concentration Quantity 100 tests Volume... more
CyFlow™ CD7 FITC
HLDA WorkshopHLDA VI—WS Code T 6T-015
Concentration
Quantity100 tests
Volume2.0 mL
ImmunogenHuman Acute Myelogenous Leukemia (AML) KG-1 cells
Background InformationCD7 (gp40) is a member of the immunoglobulin superfamily found on T cells, NK cells, thymocytes, hematopoietic progenitors, and monocytes (weakly). CD7 is also expressed on acute lymphocytic leukemia (ALL). CD7 crosslinking induces a calcium flux in T lymphocytes, presumably as a result of cytoplasmic domain association with PI3-kinase. CD7 co-stimulation can induce cytokine secretion and modulate cellular adhesion. A ligand of CD7, epithelial cell secreted protein K12, is produced in thymus to regulate thymocyte signaling and cytokine release. In lung microvascular endothelial cells CD7 serves as an IgM Fc receptor. Expression of CD7 is an important marker used in leukemia diagnostics.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·> | Alaibac M, Pigozzi B, Belloni-Fortina A, Michelotto A, Saponeri A, Peserico A: CD7 expression in reactive and malignant human skin T‑lymphocytes. Anticancer·Res. 2003·May-Jun; 23(3B):2707‑10. <·PMID:·12894562·> | Lam GK, Liao HX, Xue Y, Alam SM, Scearce RM, Kaufman RE, Sempowski GD, Haynes BF: Expression of the CD7 ligand K‑12 in human thymic epithelial cells: regulationby IFN‑gamma. J·Clin·Immunol. 2005·Jan; 25(1):41‑9. <·PMID:·15742156·> | Nishimura M, Takanashi M, Okazaki H, Satake M, Nakajima K: Role of CD7 expressed in lung microvascular endothelial cells as Fc receptor for immunoglobulin M. Endothelium. 2006·Jul-Aug; 13(4):287‑92. <·PMID:·16990185·> | Chang H, Yeung J, Brandwein J, Yi QL: CD7 expression predicts poor disease free survival and post‑remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk·Res. 2007·Feb; 31(2):157‑62. <·PMID:·16837044·>

Article successfully added.